Cyclosporine G | CAS#74436-00-3 | Immunosuppressant

MedKoo Cat#: 463055 | Name: Cyclosporine G

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cyclosporine G is a cyclic undecapeptides of fungal origin. It is an immunosuppressive agent.

Chemical Structure

Cyclosporine G

CAS#74436-00-3

Theoretical Analysis

MedKoo Cat#: 463055

Name: Cyclosporine G

CAS#: 74436-00-3

Chemical Formula: C63H113N11O12

Exact Mass: 1215.8570

Molecular Weight: 1216.66

Elemental Analysis: C, 62.19; H, 9.36; N, 12.66; O, 15.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cyclosporine G; Geclosporin; 2-norVal-cyclosporin; Cyclosporin G;

IUPAC/Chemical Name

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone

InChi Key

ZMKGDQSIRSGUDJ-VSROPUKISA-N

InChi Code

InChI=1S/C63H113N11O12/c1-25-27-29-41(15)53(76)52-57(80)66-44(28-26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27,35-48,50-53,76H,26,28-34H2,1-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b27-25+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1

SMILES Code

O=C([C@H](C(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@H](CC(C)C)N(C)C([C@H](C(C)C)NC([C@H](CC(C)C)N(C)C(CN(C)C([C@H](CCC)N1)=O)=O)=O)=O)=O)=O)=O)=O)=O)N(C)[C@@H]([C@H](O)[C@H](C)C/C=C/C)C1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,216.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Epting T, Hartmann K, Sandqvist A, Nitschke R, Gordjani N. Cyclosporin A stimulates apical Na+/H+ exchange in LLC-PK1/PKE20 proximal tubular cells. Pediatr Nephrol. 2006 Jul;21(7):939-46. doi: 10.1007/s00467-006-0097-3. Epub 2006 May 11. PMID: 16773404. 2: Poquette MA, Lensmeyer GL, Doran TC. Effective use of liquid chromatography- mass spectrometry (LC/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine. Ther Drug Monit. 2005 Apr;27(2):144-50. doi: 10.1097/01.ftd.0000148451.35811.74. PMID: 15795643. 3: Potter B, Palmer RA, Withnall R, Jenkins TC, Chowdhry BZ. Two new cyclosporin folds observed in the structures of the immunosuppressant cyclosporin G and the formyl peptide receptor antagonist cyclosporin H at ultra-high resolution. Org Biomol Chem. 2003 May 7;1(9):1466-74. doi: 10.1039/b210086j. PMID: 12926274. 4: Siuzdak G, Lewis JK. Applications of mass spectrometry in combinatorial chemistry. Biotechnol Bioeng. 1998 Spring;61(2):127-34. PMID: 10099506. 5: Potier M, Wolf A, Cambar J. Comparative study of cyclosporin A, cyclosporin G, and the novel cyclosporin derivative IMM 125 in isolated glomeruli and cultured rat mesangial cells: a morphometric analysis. Nephrol Dial Transplant. 1998 Jun;13(6):1406-11. doi: 10.1093/ndt/13.6.1406. PMID: 9641169. 6: Santori L, Rastelli M, Arena B, Morleo MA. Cyclosporine: update on pharmacology, analytical techniques and therapeutic monitoring. Boll Chim Farm. 1997 Oct;136(9):577-88. PMID: 9440351. 7: Strong ML, Ueda CT. Effects of low and high density lipoproteins on renal cyclosporine A and cyclosporine G disposition in the isolated perfused rat kidney. Pharm Res. 1997 Oct;14(10):1466-71. doi: 10.1023/a:1012141309951. PMID: 9358563. 8: Simon N, Barré J, Jolliet P, Urien S, Tillement JP. Médiateurs impliqués dans la néphrotoxicité de la ciclosporine A [Mediators involved in the nephrotoxicity of cyclosporin A]. Therapie. 1997 Jul-Aug;52(4):329-33. French. PMID: 9437887. 9: Gruber SA, Gallichio M, Rosano TG, Kaplan SS, Hughes SE, Urbauer DL, Singh TP, Lempert N, Conti DJ, Stein DS, Drusano G. Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients. J Clin Pharmacol. 1997 Jul;37(7):575-86. doi: 10.1002/j.1552-4604.1997.tb04339.x. PMID: 9243350. 10: Teofoli P, De Pità O, Lotti TM. Cyclosporin G inhibits proliferation of A431 cells in a dose- and time-dependent manner comparable to cyclosporin A. Skin Pharmacol. 1997;10(2):79-84. doi: 10.1159/000211472. PMID: 9257376. 11: Ellouk-Achard S, Martin C, Pham-Huy C, Duc HT, Thevenin M, Dutertre-Catella H, Warnet JM, Claude JR. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. Arch Toxicol. 1997;71(7):437-42. doi: 10.1007/s002040050408. PMID: 9209689. 12: Liu WT, Tamolang MB, Pang H, Ren Y, Wong PY. Semipreparative chromatographic separation of cyclosporin G metabolites generated by microsomes from rabbits treated with rifampicin. J Pharmacol Toxicol Methods. 1996 Jun;35(3):121-9. doi: 10.1016/1056-8719(96)00022-6. PMID: 8782089. 13: Fryer JP, Pascoe EA, Yatscoff RW, Thliveris JA. A comparison of cyclosporine A and cyclosporine G in a rabbit heterotopic cardiac transplant model: graft outcome and histological findings. Histol Histopathol. 1996 Apr;11(2):277-84. PMID: 8861749. 14: Gruber SA, Gallichio M, Rosano TG, Hughes SE, Singh TP, Lempert N, Conti DJ, Hasselbarth J, Freed BM, Stein D, Drusano G. Comparative pharmacokinetics of cyclosporine A and cyclosporine G in renal allograft recipients. Transplant Proc. 1996 Apr;28(2):892. PMID: 8623449. 15: Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF, Maurel P. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol. 1996 Mar 8;51(5):591-8. doi: 10.1016/s0006-2952(95)02175-2. PMID: 8615894. 16: Cohen DS, Fisher RA, Tarry WC, Tawes JW. Cardiac allograft tolerance induction with limited immunosuppression. J Surg Res. 1996 Mar;61(2):355-60. doi: 10.1006/jsre.1996.0129. PMID: 8656608. 17: Saada V, Pham-Huy C, Voisin J, Righenzi S, Rucay P, Claude JR, Duc HT. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506. Int J Immunopharmacol. 1996 Jan;18(1):79-87. doi: 10.1016/0192-0561(95)00108-5. PMID: 8732436. 18: Kovarik JM, Mueller EA, Kallay Z, Smith HT, Lison AE, Arns W, Renner E. Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation. J Clin Pharmacol. 1995 Dec;35(12):1136-43. doi: 10.1002/j.1552-4604.1995.tb04038.x. PMID: 8750363. 19: Yatscoff RW, Langman L, LeGatt DF. Therapeutic drug monitoring of cyclosporin G. Ther Drug Monit. 1995 Dec;17(6):655-9. doi: 10.1097/00007691-199512000-00018. PMID: 8588236. 20: Sallas WM. Development of limited sampling strategies for characteristics of a pharmacokinetic profile. J Pharmacokinet Biopharm. 1995 Oct;23(5):515-29. doi: 10.1007/BF02353472. PMID: 8656345.